How big is BridgeBio Pharma, Inc.?

As of Jun 18, BridgeBio Pharma, Inc. has a market capitalization of $7.86 billion, with net sales of $127.41 million and a net profit of -$676.79 million over the last four quarters. Shareholder's funds are at -$1.47 billion, and total assets amount to $919.34 million.

As of Jun 18, BridgeBio Pharma, Inc. has a market capitalization of 7,856.62 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 127.41 million, while the sum of net profit for the same period is -676.79 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -1,467.90 million and total assets at 919.34 million.

What does BridgeBio Pharma, Inc. do?

BridgeBio Pharma, Inc. develops medicines for genetic diseases and has a market cap of approximately $7.86 billion. As of March 2025, it reported net sales of $117 million and a net loss of $170 million.

Overview: <BR>BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases within the Pharmaceuticals & Biotechnology industry, classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 117 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -170 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 7,856.62 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.10 <BR>Return on Equity: 39.24% <BR>Price to Book: -4.77<BR><BR>Contact Details: <BR>Address: 421 Kipling St, PALO ALTO CA: 94301-1530 <BR>Tel: 1 650 3919740 <BR>Fax: 1 302 6555049 <BR>Website: http://bridgebio.com/

Should I buy, sell or hold BridgeBio Pharma, Inc.?

Who are in the management team of BridgeBio Pharma, Inc.?

As of March 2022, the management team of BridgeBio Pharma, Inc. includes Dr. Neil Kumar (CEO), Dr. Charles Homcy (Chairman of Pharmaceuticals), Dr. Richard Scheller (Chairman of R&D), and several independent directors: Dr. Eric Aguiar, Ms. Jennifer Cook, Mr. Ronald Daniels, Andrew Lo, and Mr. James Momtazee. This team offers a diverse range of expertise.

As of March 2022, the management team of BridgeBio Pharma, Inc. includes the following individuals:<BR><BR>- Dr. Neil Kumar, Chief Executive Officer and Director<BR>- Dr. Charles Homcy, Chairman of Pharmaceuticals and Lead Director<BR>- Dr. Richard Scheller, Chairman of Research and Development and Director<BR>- Dr. Eric Aguiar, Independent Director<BR>- Ms. Jennifer Cook, Independent Director<BR>- Mr. Ronald Daniels, Independent Director<BR>- Andrew Lo, Independent Director<BR>- Mr. James Momtazee, Independent Director<BR><BR>This team brings a diverse range of expertise to the company.

Is BridgeBio Pharma, Inc. overvalued or undervalued?

BridgeBio Pharma, Inc. is currently classified as risky due to its overvaluation indicated by negative valuation ratios, despite a strong year-to-date stock performance of 94.35%, which significantly exceeds the S&P 500's 12.22% return.

As of 7 November 2019, the valuation grade for BridgeBio Pharma, Inc. moved from does not qualify to risky. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -4.59, an EV to EBIT of -13.70, and an EV to EBITDA of -13.82. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have fair valuations with P/E ratios of 19.09 and 15.17, respectively, highlighting the relative overvaluation of BridgeBio.<BR><BR>Despite its overvaluation, BridgeBio has shown strong stock performance, with a year-to-date return of 94.35%, significantly outperforming the S&P 500's return of 12.22% over the same period. However, the company's negative return on capital employed (ROCE) of -419.24% and the overall risky classification suggest caution for potential investors.

Is BridgeBio Pharma, Inc. technically bullish or bearish?

As of October 3, 2025, BridgeBio Pharma, Inc. has a mildly bullish technical trend, supported by bullish indicators in MACD and Bollinger Bands, despite a mildly bearish KST signal, and it has significantly outperformed the S&P 500 year-to-date and over the past year.

As of 3 October 2025, the technical trend for BridgeBio Pharma, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the KST shows a mildly bearish signal. The daily moving averages are bullish, supporting the mildly bullish trend. The Dow Theory also reflects a mildly bullish outlook on both weekly and monthly timeframes. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 99.02% compared to 14.18%, and over the past year with a return of 116.45% against 17.82%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish indicators in MACD and Bollinger Bands.